Pharmaceuticals

Retinal Biologics Market Size and Growth Forecast for Businesses 2025–2029

November 7, 2025November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Retinal Biologics Market Size During 2025–2029?

The retinal biologics market size has seen rapid expansion in recent years. It is forecast to rise from $25.17 billion in 2024 to $28.12 billion in 2025, achieving a compound annual growth rate (CAGR) of 11.7%. This historic period’s growth can be attributed to the increased incidence of retinal disorders, an aging population, rising awareness and early diagnosis, evolving healthcare infrastructure, and increasing healthcare expenditure.

The retinal biologics market is expected to experience substantial growth in the upcoming years, with its size projected to reach $43.55 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 11.6%. This expansion during the forecast period is attributed to widening therapeutic applications, personalized medicine, growth in emerging markets, a strong pipeline of biologics, strategic collaborations and partnerships, and governmental support and initiatives. Noteworthy trends for this period include the development of non-invasive delivery methods, increased utilization of real-world evidence, broader indications for existing treatments, streamlined regulatory pathways, and an emphasis on patient-centric outcomes.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11911&type=smp

Which Drivers Are Shaping The Retinal Biologics Industry’s Market Share?

The rising occurrence of diabetic eye disease is projected to boost the expansion of the retinal biologics market in the future. This condition, a complication of diabetes, impacts vision by leading to loss of sight and blindness among diabetic individuals. Retinal biologics offer the promise of more accurate and potent treatment methods, enabling earlier intervention and better results in averting vision impairment linked to diabetic eye disease. An example illustrating this is the data from the Australian Bureau of Statistics, an Australia-based government agency, which reported in December 2023 that 5.3% of the Australian population (approximately 1.3 million people) suffered from diabetes in 2022, a significant increase from 3.3%. Consequently, the growing occurrence of diabetic eye disease is a key factor driving the expansion of the retinal biologics market.

What Are The Emerging Segments Gaining Attention In The Retinal Biologics Market?

The retinal biologics market covered in this report is segmented –

1) By Drug Class: Vascular Endothelial Growth Factor (VEGF)-A Antagonist, Tumor Necrosis Factor (TNF)-A Inhibitor

2) By Indication: Macular Degeneration, Diabetic Retinopathy, Uveitis, Diabetic Macular Edema, Other Indications

3) By Distribution Channel: Hospitals, Pharmacies, Specialty Clinics, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Vascular Endothelial Growth Factor (VEGF)-A Antagonist: Monoclonal Antibodies, Small Molecule Inhibitors

2) By Tumor Necrosis Factor (TNF)-A Inhibitor: Monoclonal Antibodies, Fusion Proteins

What Trends Are Expected To Drive The Retinal Biologics Market?

A prominent and growing development within the retinal biologics market is product innovation. Leading companies operating in the retinal biologics market are focusing their efforts on creating novel products to enhance their market position and gain a competitive edge. For example, in May 2023, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare firm, announced that the U.S. Food and Drug Administration had accepted its supplemental biologics license application (sBLA) for Vabysmo (faricimab), intended for the treatment of macular edema following retinal vein occlusion (RVO). This acceptance was based on the findings from two Phase III trials, which demonstrated early and sustained visual improvement with Vabysmo, successfully achieving the primary endpoint of non-inferiority compared to aflibercept. Vabysmo is notably the first bispecific antibody approved for ocular use to address neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema. Subsequent studies further revealed an absence of blood vessel leakage in the retina among Vabysmo patients, in contrast to those treated with aflibercept.

Who Are The Primary Competitors In The Global Retinal Biologics Market?

Major companies operating in the retinal biologics market include Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Novartis AG, Amgen Inc., Spark Therapeutics Inc., Bayer AG, Bausch Health Companies Inc., Merck & Co. Inc., Santen Pharmaceutical Co. Ltd., Pfizer Inc., Boehringer Ingelheim, Eyenovia Inc., EyePoint Pharmaceuticals Inc., Iveric Bio Inc., Kodiak Sciences Inc., Aerie Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., Acucela Inc., Clearside Biomedical Inc., Ophthotech Corporation, Xcovery Holdings, Athenex Inc., Fidia Farmaceutici S.p.A, Eton Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/retinal-biologics-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Retinal Biologics Market?

North America was the largest region in the retinal biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Retinal Biologics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=11911&type=smp

Browse Through More Reports Similar to the Global Retinal Biologics Market 2025, By The Business Research Company

Site Remediation Consulting Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/site-remediation-consulting-services-global-market-report

Psoriasis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Scientific Research And Development Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/scientific-research-and-development-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795